Targets › AGTR1
18 programs from 18 companies in 169 trials: 57 Phase 2, 53 Phase 4, 33 Phase 1, 26 Phase 3; Cardiovascular, Oncology, Neurology; next expected readout Nov 2026.
Receptor for angiotensin II, a vasoconstricting peptide, which acts as a key regulator of blood pressure and sodium retention by the kidney. The activated receptor in turn couples to G-alpha proteins G(q) (GNAQ, GNA11, GNA14 or GNA15) and thus activates phospholipase C and increases the cytosolic Ca(2+) concentrations, which in turn triggers cellular responses such as stimulation of protein kinase C..; FUNCTION:…. (UniProt, P30556)
Open in Phaseline: the race on AGTR1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Brigham and Women's Hospital | MIB 626 (NMN) Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist | SLC5A2, SLC6A2, GLP1R, UNKNOWN, Tubulin, OPRM1, NR3C2, AGTR1, IL4R, SLC6A4, HTR2A, HTR2C | Phase 4 | Prostate Cancer; Stable Coronary Disease; Allergic Contact Dermatitis; Hypertension … | Nov 2026 |
| University of California, San Francisco | Intravenous TXA Interleukin-23 inhibitor | ADRB2, AGTR1, IL12B, IL23A, PDCD1, NR3C1, HTR2A, MAP2K1, MAP2K2, MS4A1, CHRM3, CHRM2, ADRB3, OPRM1, CYP19A1, CHRNB2, CHRNA4 | Phase 4 | Child Mortality; Relapsing Multiple Sclerosis; Menstrual Regulation; Secondhand Smoke … | Dec 2026 |
| Travere Therapeutics | Sparsentan Endothelin receptor ET-A antagonist; Type-1 angiotensin II receptor antagonist | EDNRA, AGTR1 | Phase 4 | Proteinuria; Immunoglobulin A Nephropathy; Focal Segmental Glomerulosclerosis; ANCA Associated Vasculitis | Mar 2027 |
| National Heart Centre Singapore | Renin-angiotensin-aldosterone system inhibitors (ACE inhibitors, Angiotensin II ACE inhibition and angiotensin II receptor antagonism | ACE, AGTR1 | Phase 4 | Diabetes Mellitus | Jun 2034 |
| Yan Li | Alisartan Angiotensin II receptor antagonist | AGTR1 | Phase 4 | Hypertension | – |
| Shenzhen Salubris Pharmaceuticals | Losartan Type-1 angiotensin II receptor antagonist | AGTR1 | Phase 4 | Healthy Participants; Atrial Fibrillation; Diabetes Mellitus, Type 2; Heart Valve Diseases … | – |
| Yuhan | Telmisartan Type-1 angiotensin II receptor antagonist | AGTR1 | Phase 4 | Essential Hypertension | – |
| Sherief Abd-Elsalam | Angiotensin receptor blockers (ARBs) Angiotensin II type 1 receptor antagonist | AGTR1 | Phase 3 | Rheumatoid Arthritis | Dec 2026 |
| THPharm | Telmisartan (THP-00102) Type-1 angiotensin II receptor antagonist | AGTR1 | Phase 3 | Type 2 Diabetes; Parkinsons Disease (PD); Ovarian Cancer; Prostate Cancer | Dec 2026 |
| Chong Kun Dang Pharmaceutical | Valsartan Type-1 angiotensin II receptor antagonist | AGTR1 | Phase 3 | Essential Hypertension; Stage D Heart Failure; PreDiabetes; Coronary Artery Disease … | Dec 2026 |
| Chia Tai Tianqing Pharmaceutical Group | Angiotensin Ii Type-1 angiotensin II receptor agonist | AGTR1 | Phase 3 | Vasodilatory Shock; Vasodilatory Hypotension During or After Cardiac Surgery; Cirrhosis, Liver; Septic Shock … | Jun 2027 |
| Assistance Publique - Hôpitaux de Paris | IRBESARTAN Type-1 angiotensin II receptor antagonist | AGTR1 | Phase 3 | Acute Kidney Injury | – |
| OHSU Knight Cancer Institute | Losartan Potassium Type-1 angiotensin II receptor antagonist | AGTR1 | Phase 2 | Pancreatic Adenocarcinoma | Jan 2027 |
| HB BioTech | HB-1 Angiotensin II receptor antagonist (telmisartan) and calcium channel blocker (verapamil) | AGTR1, Ion channels | Phase 2 | PTSD | Sep 2027 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Olmesartan Type-1 angiotensin II receptor antagonist | AGTR1 | Phase 2 | HR+ / HER2- Advanced Breast Cancer | Jun 2028 |
| Shin Poong Pharmaceutical | Candesartan (SPC1001) Type-1 angiotensin II receptor antagonist | AGTR1 | Phase 2 | Hypertension, Essential; Cardiomyopathy, Dilated; Liver Fibroses | – |
| Steadman Philippon Research Institute | Losartan potassium Type-1 angiotensin II receptor antagonist | AGTR1 | Phase 1 | Knee Arthroplasty, Total | Jun 2027 |
| David K Carroll | Arginine hydrochloride L-arginine nitric oxide donor; stimulates pancreatic insulin secretion via nitric oxide-me | AGTR1 | Phase 1 | Diabetes (DM) | Oct 2027 |
Obstructive Sleep Apnea (4) Type 2 Diabetes (3) Prostate Cancer (3) Essential Hypertension (3) Hypertension (3) Nicotine Dependence (3) PreDiabetes (2) Breast Cancer (2) Heart Failure (2) Heart Failure With Reduced Ejection Fraction (2) Diabetes Mellitus (2) Proteinuria (2)
small molecule (15), mixed (2)
THPharm (1) Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) HB BioTech (1) Chong Kun Dang Pharmaceutical (1) Yuhan (1) Shenzhen Salubris Pharmaceuticals (1) Travere Therapeutics (1) Yan Li (1) Steadman Philippon Research Institute (1) Sherief Abd-Elsalam (1) David K Carroll (1) University of California, San Francisco (1) Brigham and Women's Hospital (1) National Heart Centre Singapore (1) Assistance Publique - Hôpitaux de Paris (1) Shin Poong Pharmaceutical (1) Chia Tai Tianqing Pharmaceutical Group (1) OHSU Knight Cancer Institute (1)
HTR2A (2) OPRM1 (2) Ion channels (1) EDNRA (1) ADRB2 (1) IL12B (1) IL23A (1) PDCD1 (1) NR3C1 (1) MAP2K1 (1) MAP2K2 (1) MS4A1 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.